Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era: CMAJ
Canadian Medical Association. Journal
; 193(15), 2021.
Article
in English
| ProQuest Central | ID: covidwho-1181981
ABSTRACT
Across Canada, both influenza and respiratory syncytial virus (RSV) have been almost completely absent during the 2020/21 winter. Data from the Southern hemisphere showed the same phenomenon following the implementation of public health measures for coronavirus disease 2019. Despite the low incidence of RSV, programs across Canada have continued to promote the administration of palivizumab (PVZ) prophylaxis to eligible infants at a cost of about $1500 per dose. Canadian taxpayers are currently on track to spend nearly $50 million on a drug unlikely to have any benefit this winter. Here, the effectiveness of PVZ prophylaxis for infants is examined.
Search on Google
Collection:
Databases of international organizations
Database:
ProQuest Central
Language:
English
Journal:
Canadian Medical Association. Journal
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS